Raynaud's phenomenon pharmacologic treatment typically involves which class of drugs?

Raynaud's phenomenon pharmacologic treatment typically involves which class of drugs?

• A. Non-dihydropyridine calcium channel blockers
• B. Dihydropyridine calcium channel blockers
• C. Beta-blockers
• D. ACE inhibitors

Answer: (B)

Raynaud's phenomenon is driven by reversible vasospasm of small digital arteries, especially in response to cold or stress. The goal of pharmacologic treatment is to promote vasodilation in those peripheral vessels to improve blood flow during attacks. Dihydropyridine calcium channel blockers are the best fit for this purpose because they preferentially dilate vascular smooth muscle in peripheral arteries. By blocking L-type calcium channels, these drugs reduce intracellular calcium in the smooth muscle, causing relaxation and widening of the digital arteries. This directly reduces the frequency and severity of vasospastic episodes; examples like nifedipine or amlodipine are commonly used. Non-dihydropyridine calcium channel blockers can help but tend to have more cardiac effects (such as bradycardia or conduction slowing), which makes them less ideal as first-line for Raynaud's. Beta-blockers may worsen vasospasm in the hands, and ACE inhibitors are not standard first-line therapies for this condition.

Raynaud's phenomenon is driven by reversible vasospasm of small digital arteries, especially in response to cold or stress. The goal of pharmacologic treatment is to promote vasodilation in those peripheral vessels to improve blood flow during attacks. Dihydropyridine calcium channel blockers are the best fit for this purpose because they preferentially dilate vascular smooth muscle in peripheral arteries. By blocking L-type calcium channels, these drugs reduce intracellular calcium in the smooth muscle, causing relaxation and widening of the digital arteries. This directly reduces the frequency and severity of vasospastic episodes; examples like nifedipine or amlodipine are commonly used.

Non-dihydropyridine calcium channel blockers can help but tend to have more cardiac effects (such as bradycardia or conduction slowing), which makes them less ideal as first-line for Raynaud's. Beta-blockers may worsen vasospasm in the hands, and ACE inhibitors are not standard first-line therapies for this condition.